Latest news with #Omnipod5
Yahoo
2 days ago
- Business
- Yahoo
PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption
Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter's revenue guidance ($608.2 million at the midpoint) was surprisingly good and 5.5% above what analysts were expecting. Its non-GAAP profit of $1.02 per share was 29.7% above analysts' consensus estimates. Is now the time to buy PODD? Find out in our full research report (it's free). Revenue: $569 million vs analyst estimates of $543 million (28.8% year-on-year growth, 4.8% beat) Adjusted EPS: $1.02 vs analyst estimates of $0.79 (29.7% beat) Revenue Guidance for Q2 CY2025 is $608.2 million at the midpoint, above analyst estimates of $576.3 million Operating Margin: 15.6%, up from 12.9% in the same quarter last year Constant Currency Revenue rose 29.8% year on year (22.8% in the same quarter last year) Market Capitalization: $21.51 billion Insulet's first quarter results reflected continued momentum in automated insulin delivery, driven by robust demand for the Omnipod 5 platform across both U.S. and international markets. Management cited commercial execution, with CEO Ashley McEvoy emphasizing the company's unique positioning at the intersection of consumer health and medical technology. The team pointed to growth in new customer starts for both type 1 and type 2 diabetes, with over 85% of U.S. new starts coming from multiple daily injection (MDI) users and more than 30% from type 2 patients. CFO Ana Chadwick highlighted operational improvements and manufacturing efficiencies, resulting in gross margin expansion and stable retention rates, especially following the launch of Omnipod 5 in new international markets. Looking ahead, Insulet's guidance for the next quarter and the full year is underpinned by ongoing investments in product innovation, expanded commercial reach, and international market launches. CEO Ashley McEvoy stated that the company's priorities remain focused on advancing technology, driving growth in both type 1 and type 2 diabetes segments, and expanding Omnipod 5's global footprint. She noted, 'Our strategy is intact. We will continue to drive robust growth and do so profitably on a global scale.' Management also discussed the impacts of tariffs and supply chain dynamics, but expressed confidence in maintaining margin expansion through efficiency gains and scale. Omnipod 5 launches in new countries and continued direct-to-consumer marketing are expected to further support growth. Management attributed the quarter's performance to strong Omnipod 5 adoption, commercial investments, and operational discipline across manufacturing and supply chain. Type 2 diabetes expansion: The U.S. launch of Omnipod 5 for type 2 diabetes contributed to over 30% of new customer starts in the quarter, supported by a recently expanded sales force and targeted direct-to-consumer advertising. International growth momentum: International markets saw Omnipod 5 launches in Canada and Switzerland, bringing the total to 13 countries, with further expansion planned in the Middle East. International new customer starts increased sequentially, driven by new sensor integrations and customer upgrades. Advances in automation and manufacturing: Investments in advanced automation and the ramp-up of the Malaysia facility were cited as key drivers of gross margin expansion. Management stated the Malaysia site is on track to be accretive to margins by the third quarter. Direct-to-consumer (DTC) strategy: Higher conversion rates from DTC efforts are bringing more interested patients into the Omnipod ecosystem. Management highlighted more efficient advertising spend and improved lead conversion. Stable retention and utilization: Retention rates remained steady in the U.S. and improved internationally with Omnipod 5 adoption. Utilization metrics for new type 2 users closely mirrored those for type 1, with only slightly higher attrition, as expected by management. Insulet expects continued growth, supported by Omnipod 5 adoption, expansion into new markets, and operational efficiencies, while monitoring potential risks from tariffs and international launches. Broader type 2 adoption: Management is prioritizing growth in the U.S. type 2 diabetes segment, focusing on expanding prescriber reach through a larger sales force and leveraging clinical data to promote adoption. Early results show increased prescription activity among health care providers, and management believes the market could double or triple in the coming years, though the exact pace remains uncertain. International market expansion: The company is launching Omnipod 5 in new regions, including recent entries into Canada and Switzerland and planned launches in the Middle East. Management expects international growth to be driven primarily by volume as more markets upgrade from earlier Omnipod versions, with ongoing efforts to adapt U.S. commercial strategies to fit international contexts. Margin management amid tariffs: Insulet forecasts stable gross and operating margins, despite a projected 50 basis point impact from tariffs related to China. Investments in automation and diversified manufacturing are expected to offset these pressures, and the company is raising its gross margin outlook while maintaining ongoing R&D and commercial investments. In the coming quarters, the StockStory team will be watching (1) whether Insulet can maintain momentum in type 2 diabetes adoption and expanded health care provider engagement, (2) the progress and outcomes of new international Omnipod 5 launches—particularly in the Middle East, and (3) the impact of manufacturing scale-ups and automation on gross margins. Developments in direct-to-consumer strategies and tariff management will also be important markers of execution. Insulet currently trades at a forward P/E ratio of 69.1×. At this valuation, is it a buy or sell post earnings? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Health
- Yahoo
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience ACTON, Mass., June 10, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System. With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom's latest diabetes management technology, all conveniently controlled from an iPhone. "This integration represents a major milestone in our commitment to providing innovative solutions for diabetes management," said Eric Benjamin, Insulet Executive Vice President, Chief Product and Customer Experience Officer. "With the addition of the Dexcom G7 sensor to the Omnipod 5 App for iPhone, our U.S. customers have more choice with fewer devices to keep track of, making it easier than ever to manage their diabetes." Omnipod 5 proactively adjusts insulin delivery every five minutes, autocorrects for high glucose, and helps protect against lows*, day and night—even while you sleep. The Omnipod 5 App for iPhone, available in the U.S., offers full control of Omnipod 5 including the ability to bolus, change a Pod, adjust settings, access valuable insights, and more. "The Omnipod 5 App for iPhone means less stress with better control! Plus, I feel like I lost a few pounds, since I don't have to carry around a Controller anymore," joked Garrett Vogel, a nationally syndicated radio personality who has lived with type 1 diabetes for 30 years and has been using Omnipod 5 since 2023. Garrett was previously using Omnipod 5 with Dexcom G7 and the Controller. "I thought bolusing with the Controller was easy, but the Omnipod 5 App on my iPhone makes it even easier. I love it." The Omnipod 5 App with Dexcom G7 and Dexcom G6 compatibility is now available for download on the Apple App Store. Insulet remains dedicated to advancing diabetes technology and improving the lives of people with diabetes. For more information, please visit About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: and *Brown S. et al. Diabetes Care. 2021;44:1630-1640. Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Pasquel FJ et al. JAMA Network Open. 2024;8(2): e2459348. Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people with type 2 diabetes aged 18-75 years. Time above range and below range results measured by CGM. ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners. View source version on Contacts Investor Relations: June LazaroffSenior Director, Investor Relations(978) 600-7717jlazaroff@ Media: Angela Geryak WiczekSenior Director, Corporate Communications(978) 932-0611awiczek@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
11-05-2025
- Business
- Business Insider
Analysts Turn Bullish on Insulet Stock (PODD) after Strong Q1 Earnings
Insulet Corporation (PODD), the healthcare company known for its insulin delivery system, has experienced a phenomenal week, encapsulated in its stock soaring almost 21% on Friday. It came after the company delivered a standout Q1 2025 performance, driving bullish sentiment from top Wall Street analysts. The company reported a 30% year-over-year revenue jump to $569 million, fueled by strong Omnipod sales and rapid international expansion. Gross margin climbed to 71.9%, a 240-basis-point improvement, reflecting operational efficiency gains. With rising demand in the type 2 diabetes market – now accounting for over 30% of new U.S. customers – and a successful global rollout of Omnipod 5, Insulet raised its full-year guidance, projecting company revenue growth between 19% and 22%. Protect Your Portfolio Against Market Uncertainty Analysts Are Bullish Following the results, Insulet's stock soared, reflecting investor optimism about its sustained momentum and market penetration strategy. This impressive run was echoed by analysts, with both Wells Fargo and Oppenheimer reiterating Buy ratings and increasing their price targets. Oppenheimer's five-star analyst, Steven Lichtman, raised his target from $312 to $324, suggesting an upside of 4.29%. Meanwhile, Wells Fargo's five-star analyst, Larry Biegelsen, went further, lifting his target from $322 to $330, suggesting a 6.22% upside potential. Morgan Stanley's (MS) Patrick Wood also joined the bullish choir. He reiterated his Buy rating on Insulet and a price target of $325, suggesting a 4.61% upside. He highlighted strong U.S. and international growth, especially in type 2 diabetes adoption, and a notable margin beat, signaling operational efficiency. Another was William Blair's Margaret Kaczor, who maintained a Buy rating, citing Insulet's Q1 sales beat and raising full-year guidance. Most Wall Street analysts generally see PODD's leadership under new CEO Ashley McEvoy as a positive development in expanding the company's reach and capitalizing on the substantial growth opportunity in the global insulin pump market. Wall Street is highly bullish on Insulet Corporation with a Strong Buy rating. The average price target for PODD stock is $321.88, suggesting a 3.61% upside potential.
Yahoo
09-05-2025
- Business
- Yahoo
Insulet (NasdaqGS:PODD) Announces $125M Buyback, Raises Revenue Guidance For 2025
Insulet recently announced significant corporate developments including a share repurchase program and raised revenue guidance for 2025, indicating a focus on growth and shareholder value. Over the past month, the company's stock price rose 4%, a move that aligns with the broader market trends, as the market itself climbed 1.3% in the past 7 days. This price change was amidst mixed investor anticipation of broader economic conditions including ongoing US-China trade talks, suggesting that Insulet's announcements provided some uplift, complementing rather than deviating from general market moves. Buy, Hold or Sell Insulet? View our complete analysis and fair value estimate and you decide. Uncover the next big thing with financially sound penny stocks that balance risk and reward. Insulet's recent announcements, including the share repurchase program and raised revenue guidance for 2025, highlight a strong commitment to enhancing shareholder value while pursuing growth. The expansion into the type 2 diabetes market, facilitated by the FDA clearance of Omnipod 5, is expected to increase revenue significantly, assisting in the achievement of revised targets. This growth trajectory is further bolstered by international rollouts, which, despite posing potential margin pressure, are anticipated to expand Insulet's market reach and revenue-generating capabilities. Over the past year, Insulet recorded a total shareholder return of 44.76%, indicative of strong performance amidst broader market conditions. Comparatively, the company has outperformed both the US market, which returned 7.7%, and the US Medical Equipment industry, which returned 8.8% over the same period. The increased revenue forecasts—US$3.3 billion by 2028—align with these market trends, though analysts warn that maintaining high growth rates could challenge profit margins. While the stock's current price reflects a 17.5% discount to the analyst consensus price target of US$313.60, ongoing investor sentiment may hinge on the company's ability to sustain earnings growth in the face of industry competition and potential operational costs associated with its global expansion. These factors will be crucial in determining whether current trends can drive share price movement towards the target, hinging on execution against the projected revenue and earnings benchmarks. Review our historical performance report to gain insights into Insulet's track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:PODD. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
08-05-2025
- Business
- Business Wire
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency 1)
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for the three months ended March 31, 2025. 'Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our Podders," said Ashley McEvoy, President and CEO. "I'd like to thank the team and Board of Directors for their incredible support. Insulet is just getting started on an exciting journey to revolutionize diabetes management globally. I am energized and honored to embark on that journey with all of you.' First Quarter Financial Highlights: Revenue of $569.0 million, up 28.8%, or 29.8% in constant currency, compared with $441.7 million in the prior year, exceeds the high end of the Company's guidance range of 25% in constant currency Total Omnipod revenue of $554.1 million, an increase of 28.0%, or 29.0% in constant currency U.S. Omnipod revenue of $401.7 million, an increase of 26.4% International Omnipod revenue of $152.4 million, an increase of 32.2%, or 36.1% in constant currency Drug Delivery revenue of $14.9 million Gross margin of 71.9%, up 240 basis points, compared with 69.5% in the prior year Operating income of $88.8 million, or 15.6% of revenue, up 270 basis points, compared with $56.9 million, or 12.9% of revenue, in the prior year Adjusted operating income 1 of $93.5 million, or 16.4% of revenue, up 350 basis points over prior year Net income of $35.4 million, or $0.50 per diluted share, compared with $51.5 million, or $0.73 per diluted share, in the prior year Adjusted net income 1 of $73.7 million, or $1.02 per diluted share Adjusted EBITDA 1 of $133.9 million, or 23.5% of revenue, up 330 basis points, compared with $89.2 million, or 20.2% of revenue, in the prior year Operating cash flow of $63.8 million, compared with $87.6 million in the prior year Free cash flow 1 of $51.5 million, compared with $65.5 million in the prior year Recent Strategic Highlights: Launched Omnipod 5 in Australia, Belgium, Canada, and Switzerland, marking nine new countries where Omnipod 5 has become available since the start of the year and 14 overall globally Presented RADIANT trial data at the Advanced Technologies & Treatments for Diabetes (ATTD) International Conference, which is the first randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes. Compared to people using multiple daily injections with a continuous glucose monitor, Omnipod 5 demonstrated an average reduction in HbA1c of -0.8% and an average of 5.4 hours more per day with glucose levels in the target range without an increase in hypoglycemia 2 Successfully issued $450 million senior unsecured notes and upsized and extended the maturity of revolving credit facility. Extinguished $420 million principal of convertible notes to date Board of Directors authorized a program to repurchase up to $125 million of common stock through December 31, 2026 to offset dilution from stock-based compensation 2025 Outlook: For the quarter ending June 30, 2025 and year ending December 31, 2025, the Company is providing the following guidance (revenue in constant currency): Conference Call: Insulet will host a conference call at 4:30 p.m. (Eastern Time) on May 8, 2025 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company's website at 'Events and Presentations,' and will be archived for future reference. The live call may also be accessed by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode 5904836. About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit or Non-GAAP Measures: The Company uses the following non-GAAP financial measures: Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents constant currency revenue growth because management believes it provides meaningful information regarding the Company's results on a consistent and comparable basis. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with generally accepted accounting principles in the United States (GAAP), to evaluate the Company's operating results. It is also one of the performance metrics that determines management incentive compensation. Adjusted gross margin, adjusted gross margin as a percentage of revenue, adjusted operating income, adjusted operating income as a percentage of revenue, adjusted net income, and adjusted diluted earnings per share exclude the impact of certain significant transactions or events, such as legal settlements, medical device corrections, gains (losses) on investments and loss on extinguishment of debt, that affect the period-to-period comparability of the Company's performance, as applicable. Adjusted EBITDA, which represents net income plus net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense and other significant transactions or events, such as legal settlements, medical device corrections, gains (losses) on investments and loss on extinguishment of debt, which affect the period-to-period comparability of the Company's performance, as applicable, and adjusted EBITDA as a percentage of revenue. Free cash flow, which is defined as net cash provided by operating activities less capital expenditures. Insulet presents the above non-GAAP financial measures because management uses them as supplemental measures in assessing the Company's performance, and the Company believes they are helpful to investors and other interested parties as measures of comparative performance from period to period. They also are commonly used measures in determining business value, and the Company uses them internally to report results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with GAAP. Furthermore, the Company's definition of these non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, Insulet strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Forward-Looking Statement: This press release contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements are based on management's current beliefs, assumptions and estimates and are not intended to be a guarantee of future events or performance. If management's underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by the forward-looking statements. Risks and uncertainties include, but are not limited to our dependence on a principal product platform; the impact of competitive products, technological change and product innovation; our ability to maintain an effective sales force and expand our distribution network; our ability to maintain and grow our customer base; our ability to scale the business to support revenue growth; our ability to secure and retain adequate coverage or reimbursement from third-party payors; the impact of healthcare reform laws; our ability to design, develop, manufacture and commercialize future products; unfavorable results of clinical studies, including issues with third parties conducting any studies, or future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable; our ability to protect our intellectual property and other proprietary rights; potential conflicts with the intellectual property of third parties; our inability to maintain or enter into new license or other agreements with respect to continuous glucose monitors, data management systems or other rights necessary to sell our current product and/or commercialize future products; worldwide macroeconomic and geopolitical uncertainty, as well as risks associated with public health crises and pandemics, including government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; international regulatory, commercial and logistics business risks, including the implementation of tariffs; the potential violation of anti-bribery/anti-corruption laws; the concentration of manufacturing operations and storage of inventory in a limited number of locations; supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent; failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure or that of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy and data protection laws; our use of artificial intelligence tools; adverse regulatory or legal actions relating to current or future Omnipod products; potential adverse impacts resulting from a recall, or discovery of serious safety issues, or product liability lawsuits relating to off-label use; breaches or failures of our product or information technology systems, including by cyberattack; our ability to attract, motivate, and retain key personnel; risks associated with potential future acquisitions or investments in new businesses; ability to raise additional funds on acceptable terms or at all; the volatility of the trading price of our common stock; changes in tax laws or exposure to significant tax liabilities; and risks related to the conversion of outstanding Convertible Senior Notes. For a further list and description of these and other important risks and uncertainties that may affect the Company's future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which the Company may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q the Company has filed or will file hereafter. Any forward-looking statement made in this release speaks only as of the date of this release. Insulet does not undertake to update any forward-looking statement, other than as required by law. ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. INSULET CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (dollars in millions) December 31, 2024 ASSETS Cash and cash equivalents $ 1,283.1 $ 953.4 Accounts receivable, net 402.3 365.5 Inventories 440.8 430.4 Prepaid expenses and other current assets 202.2 142.0 Total current assets 2,328.4 1,891.3 Property, plant and equipment, net 718.7 723.1 Goodwill and other intangible assets, net 151.3 150.0 Other assets 318.9 323.3 Total assets $ 3,517.3 $ 3,087.7 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable $ 57.6 $ 19.8 Accrued expenses and other current liabilities 379.7 424.8 Current portion of long-term debt 83.1 83.8 Total current liabilities 520.4 528.4 Long-term debt, net 1,612.3 1,296.1 Other liabilities 53.9 51.6 Total liabilities 2,186.6 1,876.1 Stockholders' equity 1,330.7 1,211.6 Total liabilities and stockholders' equity $ 3,517.3 $ 3,087.7 Expand INSULET CORPORATION Three Months Ended March 31, U.S. Omnipod $ 401.7 $ 317.7 26.4% —% 26.4% International Omnipod 152.4 115.3 32.2% (3.9)% 36.1% Total Omnipod 554.1 433.0 28.0% (1.0)% 29.0% Drug Delivery 14.9 8.7 71.3% —% 71.3% Total $ 569.0 $ 441.7 28.8% (1.0)% 29.8% Expand ADJUSTED OPERATING INCOME, NET INCOME & DILUTED EPS Three Months Ended March 31, 2025 (in millions, except per share data) Operating Income Income before Income Taxes Net Income (4) Net Income, Diluted Diluted Earnings per Share Effective Tax Rates GAAP $ 88.8 $ 48.1 $ 35.4 $ 37.2 $ 0.50 26.4% Loss on investments (1) 4.7 7.5 5.8 5.8 $ 0.08 Loss on extinguishment of debt (2) — 39.5 39.0 39.0 $ 0.53 Tax matters (3) — — (6.5) (6.5) $ (0.09) Non-GAAP $ 93.5 $ 95.1 $ 73.7 $ 75.5 $ 1.02 22.6% (1) Represents a provision for credit loss included in selling, general and administrative expenses related to a debt investment and an impairment included in other expense related to an equity investment. (2) Relates to the repurchase of a portion of the Company's convertible debt. (3) Primarily represents consolidating effective tax rate adjustment related to non-GAAP items and excess tax benefits related to employee share-based compensation. (4) The tax effect on non-GAAP adjustments is calculated based on applicable local statutory rates. Expand INSULET CORPORATION ADJUSTED EBITDA Three Months Ended March 31, (dollars in millions) 2025 Percent of Revenue 2024 Percent of Revenue Net income $ 35.4 6.2% $ 51.5 11.7% Interest (income) expense, net (1.1 ) 1.3 Income tax expense 12.7 3.4 Depreciation and amortization 21.7 18.8 Stock-based compensation expense 18.2 14.2 Loss on extinguishment of debt (1) 39.5 — Loss on investments (2) 7.5 — Adjusted EBITDA $ 133.9 23.5% $ 89.2 20.2% (1) Relates to the repurchase of a portion of the Company's convertible debt. (2) Represents a provision for credit loss related to a debt investment and an impairment related to an equity investment. Expand FREE CASH FLOW Three Months Ended March 31, (dollars in millions) 2025 2024 Net cash provided by operating activities $ 63.8 $ 87.6 Capital expenditures (12.3 ) (22.1 ) Free cash flow $ 51.5 $ 65.5 Expand INSULET CORPORATION REVENUE GUIDANCE Year Ending December 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 18% - 21% —% 18% - 21% International Omnipod 29% - 32% 2% 27% - 30% Total Omnipod 21% - 24% 1% 20% - 23% Drug Delivery (35)% - (25)% —% (35)% - (25)% Total 20% - 23% 1% 19% - 22% Expand Three Months Ended June 30, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 22% - 25% —% 22% - 25% International Omnipod 32% - 35% 5% 27% - 30% Total Omnipod 24% - 27% 1% 23% - 26% Drug Delivery 10% - 15% —% 10% - 15% Total 24% - 27% 1% 23% - 26% Expand
